Pfizer's financial history over the 2018–2023 period is among the most dramatic in large-cap corporate history: a period of modest revenue that transformed into an extraordinary COVID windfall, followed by a sharp normalization that required fundamental restructuring. Understanding this arc is essential to evaluating Pfizer's current financial condition and medium-term earnings trajectory. In the three years preceding the pandemic (FY2018–FY2020), Pfizer generated revenues in the range of $51–53 billion annually, reflecting a stable but slowly declining portfolio as key drugs faced generic competition (Lyrica's US patent expired in December 2018, creating a significant revenue headwind). Net income in this period was approximately $11–16 billion, reflecting the high margins of patent-protected branded pharmaceuticals offset by substantial R&D investment and amortization of acquired intangible assets. The COVID windfall was staggering in its magnitude and velocity. Comirnaty revenues reached $36.8 billion in 2022, while Paxlovid generated $18.9 billion in the same year — combined COVID product revenues of approximately $56.7 billion on top of Pfizer's pre-existing base business of approximately $43 billion. Total 2022 revenues of $100.3 billion represented a doubling of the pre-pandemic run rate, and generated net income of approximately $31.4 billion. The company's cash generation was extraordinary: free cash flow exceeded $25 billion in 2022, funding the acquisition campaign described above with minimal leverage. The normalization in 2023 was equally dramatic. Comirnaty revenues fell to approximately $11.2 billion (from $36.8 billion in 2022), and Paxlovid revenues fell to approximately $13.9 billion (from $18.9 billion). Total 2023 revenues were approximately $58.5 billion — a 42% decline year-over-year — and reported net income was approximately $2.1 billion, reflecting large impairment charges on COVID inventory write-downs and acquisition-related amortization from the Seagen deal. Adjusted (non-GAAP) earnings, which exclude these non-cash items, were approximately $11–12 billion, more representative of the underlying business economics. The balance sheet transformation was significant. The acquisitions funded from COVID proceeds — primarily Seagen at $43 billion — substantially increased Pfizer's debt load. Net debt rose from a near-zero position in 2021–22 to approximately $30–35 billion by end-2023, as the acquisition pace outran even the extraordinary cash generation. The cost restructuring program — announced in late 2023 with a target of $3.5 billion in annualized savings by end-2024 — reflects the need to right-size the cost base for a revenue base that is approximately $40 billion lower than the COVID peak. Pfizer's pipeline assets — the acquired oncology portfolio from Seagen, the mRNA platform investments, and the internal R&D programs in rare disease and immunology — represent off-balance-sheet value that financial metrics do not fully capture. The market's assessment of Pfizer's long-term revenue trajectory, which determines the stock's price-to-earnings multiple, has been cautious: the stock has traded at a significant discount to the broader pharmaceutical peer group since the 2022 revenue peak, reflecting uncertainty about whether the acquired pipeline can deliver revenues sufficient to offset COVID normalization and ongoing base business patent expiries.